Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Meagan C. Fitzpatrick: received grants to her institution from the National Institutes of Health, National Science Foundation, World Health Organization, and Bill & Melinda Gates Foundation; consulting fees from Sanofi Pasteur and The Commonwealth Fund. Rachel S. Laufer: none to declare. Ranju Baral: none to declare. Amanda Driscoll: none to declare. Danny Feikin : none to declare. Jessica A. Fleming: none to declare. Mark Jit: Mark Jit is an unpaid member of the Respiratory Syncytial Virus Consortium in Europe (RESCEU) and Preparing for RSV Immunisation and Surveillance in Europe (PROMISE). RESCEU and PROMISE have received funding from the Innovative Medicines Initiative 2 Joint Undertaking. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. Neither MJ nor his research group has received any forms of pecuniary or other support from the pharmaceutical industry. Sonnie Kim: none to declare. Mihaly Koltai: none to declare. You Li: Grants to his institutions from Wellcome Trust and GSK; personal fees from Pfizer, all outside the submitted work. Xiao Li: none to declare. Harish Nair: Received funding from Innovative Medicines Initiative, National Institute of Health Research, Pfizer, and Icosavax; Consultancies from Sanofi, Pfizer, GSK, MSD, ReViral, Icosavax, Astra Zeneca, and Abbvie all outside submitted work. Kathleen M. Neuzil: Is a member of the WHO Strategic Advisory Group of Experts on Immunization. Clint Pecenka: none to declare. Erin Sparrow: none to declare. Padmini Srikantiah: none to declare. Justin R. Ortiz: Grants to his institution from the National Science Foundation, Bill & Melinda Gates Foundation, Pfizer, NIH, and World Health Organization; consulting fees from Putnam and GSK; and participation on advisory boards for Pfizer, Seqirus, and Moderna, all outside the submitted work]."

"Funding: This meeting was funded by a grant from the Bill & Melinda Gates Foundation (Global Health Grant OPP1114766) to the World Health Organization, which sponsored the meeting."